Q2 Earnings Forecast for RYTM Issued By HC Wainwright

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Research analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Rhythm Pharmaceuticals in a note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.40) for the quarter. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.18) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). The company had revenue of $41.83 million for the quarter, compared to the consensus estimate of $38.48 million. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%.

A number of other equities research analysts also recently weighed in on the company. Morgan Stanley restated an “overweight” rating and set a $72.00 price target on shares of Rhythm Pharmaceuticals in a research report on Friday, March 7th. Canaccord Genuity Group raised their price objective on Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Stifel Nicolaus started coverage on Rhythm Pharmaceuticals in a research note on Wednesday, March 5th. They issued a “buy” rating and a $78.00 target price for the company. Needham & Company LLC lifted their price target on shares of Rhythm Pharmaceuticals from $64.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, March 18th. Finally, The Goldman Sachs Group boosted their price objective on shares of Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $69.46.

Rhythm Pharmaceuticals Stock Performance

NASDAQ RYTM opened at $54.30 on Tuesday. Rhythm Pharmaceuticals has a 52-week low of $35.17 and a 52-week high of $68.58. The company has a fifty day moving average of $55.26 and a 200-day moving average of $55.02. The company has a market capitalization of $3.43 billion, a P/E ratio of -12.54 and a beta of 2.30.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other news, CAO Christopher Paul German sold 635 shares of the company’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total transaction of $36,334.70. Following the completion of the transaction, the chief accounting officer now directly owns 2,070 shares of the company’s stock, valued at approximately $118,445.40. This represents a 23.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO David P. Meeker sold 4,278 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total value of $254,241.54. Following the completion of the sale, the chief executive officer now directly owns 189,927 shares in the company, valued at $11,287,361.61. The trade was a 2.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 108,131 shares of company stock valued at $5,781,098 in the last quarter. Company insiders own 5.60% of the company’s stock.

Institutional Trading of Rhythm Pharmaceuticals

Several large investors have recently bought and sold shares of RYTM. SRS Capital Advisors Inc. lifted its position in Rhythm Pharmaceuticals by 740.7% during the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock valued at $25,000 after acquiring an additional 400 shares during the period. Raleigh Capital Management Inc. purchased a new position in Rhythm Pharmaceuticals in the fourth quarter worth about $28,000. SBI Securities Co. Ltd. bought a new stake in Rhythm Pharmaceuticals during the fourth quarter valued at approximately $37,000. R Squared Ltd bought a new stake in shares of Rhythm Pharmaceuticals during the 4th quarter valued at $44,000. Finally, State of Wyoming bought a new stake in Rhythm Pharmaceuticals during the fourth quarter valued at about $61,000.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.